Nonalcoholic fatty liver disease: New drug proves 'safe and effective'

Researchers in Austria are examining a new treatment for NAFLD.

Scientists are studying nor-urso, a modified version of ursodeoxycholic acid, a common oral drug that can alter the makeup of bile and may dissolve gallstones. The study authors stated, “In conclusion, a 1,500-mg dosage of nor-urso “resulted in a significant reduction of serum ALT within 12 weeks of treatment, when compared with placebo.”

The findings have been published in The Lancet Gastroenterology & Hepatology.

A double-blind, placebo-controlled randomized clinical trial finds the right dosage at which a drug ‘safely’ treats nonalcoholic fatty liver disease.

Read full article ↗